Compare LTC Properties Inc (LTC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs TG Therapeutics Inc — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.6× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and TG Therapeutics Inc for 16 Days on average.
| LTC | TGTX | |
|---|---|---|
Market Cap | $2.27B | $8.16B |
Volume | 574,171 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $59.06 |
52-Week Low | $33.98 | $26.94 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $3.01B | $8.37B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with a mixed technical picture showing bearish overall signals but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with steady income from monthly dividends and strategic SHOP portfolio expansion, though elevated debt levels and rising interest rates pose headwinds. The stock trades below analyst targets but faces execution risks in its transition to 75% SHOP NOI by 2028.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
